EP1854476A2 - Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten - Google Patents

Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten Download PDF

Info

Publication number
EP1854476A2
EP1854476A2 EP07008840A EP07008840A EP1854476A2 EP 1854476 A2 EP1854476 A2 EP 1854476A2 EP 07008840 A EP07008840 A EP 07008840A EP 07008840 A EP07008840 A EP 07008840A EP 1854476 A2 EP1854476 A2 EP 1854476A2
Authority
EP
European Patent Office
Prior art keywords
relaxin
rhrlx
rats
vegf
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07008840A
Other languages
English (en)
French (fr)
Other versions
EP1854476A3 (de
Inventor
Kirk P. Conrad
Martyn Lewis
Elaine N. Unemori
Xinfan Huang
Carol A. Tozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
University of Pittsburgh
Corthera Inc
Original Assignee
Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, University of
Rutgers State University of New Jersey
University of Pittsburgh
BAS Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, University of, Rutgers State University of New Jersey, University of Pittsburgh, BAS Medical Inc filed Critical Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, University of
Priority claimed from EP01909098A external-priority patent/EP1253929B1/de
Publication of EP1854476A2 publication Critical patent/EP1854476A2/de
Publication of EP1854476A3 publication Critical patent/EP1854476A3/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07008840A 2000-02-09 2001-02-09 Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten Withdrawn EP1854476A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18140800P 2000-02-09 2000-02-09
US20028400P 2000-04-28 2000-04-28
US24221600P 2000-10-20 2000-10-20
EP01909098A EP1253929B1 (de) 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP01909098A Division EP1253929B1 (de) 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Publications (2)

Publication Number Publication Date
EP1854476A2 true EP1854476A2 (de) 2007-11-14
EP1854476A3 EP1854476A3 (de) 2008-05-07

Family

ID=38573250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07008840A Withdrawn EP1854476A3 (de) 2000-02-09 2001-02-09 Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten

Country Status (1)

Country Link
EP (1) EP1854476A3 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
EP0345242A2 (de) 1988-06-03 1989-12-06 Smithkline Biologicals S.A. Expression von retroviralen GAG-Proteinen in eukaryontischen Zellen
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0415731A2 (de) 1989-08-30 1991-03-06 The Wellcome Foundation Limited Neue Substanzen für die Krebstherapie
WO1992011033A1 (en) 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
WO1993009239A1 (en) 1991-11-08 1993-05-13 Research Corporation Technologies, Inc. Adeno-associated virus-2 basal vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993011230A1 (en) 1991-12-02 1993-06-10 Dynal As Modified mammalian stem cell blocking viral replication
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1993019191A1 (fr) 1992-03-16 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des cytokines pour traitement antitumoral
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
WO1994003622A1 (en) 1992-07-31 1994-02-17 Imperial College Of Science, Technology & Medicine D-type retroviral vectors, based on mpmv
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
WO1994028938A1 (en) 1993-06-07 1994-12-22 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy sponsorship
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
WO1995005266A1 (en) 1993-08-16 1995-02-23 Sierra Machinery, Inc. Dual roller burnishing system
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2145515A1 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
EP0345242A2 (de) 1988-06-03 1989-12-06 Smithkline Biologicals S.A. Expression von retroviralen GAG-Proteinen in eukaryontischen Zellen
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0415731A2 (de) 1989-08-30 1991-03-06 The Wellcome Foundation Limited Neue Substanzen für die Krebstherapie
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1992011033A1 (en) 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993009239A1 (en) 1991-11-08 1993-05-13 Research Corporation Technologies, Inc. Adeno-associated virus-2 basal vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993011230A1 (en) 1991-12-02 1993-06-10 Dynal As Modified mammalian stem cell blocking viral replication
WO1993019191A1 (fr) 1992-03-16 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des cytokines pour traitement antitumoral
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
WO1994003622A1 (en) 1992-07-31 1994-02-17 Imperial College Of Science, Technology & Medicine D-type retroviral vectors, based on mpmv
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
WO1994028938A1 (en) 1993-06-07 1994-12-22 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy sponsorship
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
WO1995005266A1 (en) 1993-08-16 1995-02-23 Sierra Machinery, Inc. Dual roller burnishing system
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
BABA ET AL., J. NEUROSURG., vol. 79, 1993, pages 729 - 735
BERKNER, BIOTECHNIQUES, vol. 6, 1988, pages 616 - 627
CONNELLY, HUMAN GENE THERAPY, vol. 1, 1995, pages 185 - 193
CURIEL, HUM. GENE THER., vol. 3, 1992, pages 147 - 154
FLOTTE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10613 - 10617
JOLLY, CANCER GENE THERAPY, vol. 1, 1994, pages 51 - 64
KAPLITT, NATURE GENETICS, vol. 6, 1994, pages 148 - 153
KASS-EISLER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 11498 - 11502
KIMURA, HUMAN GENE THERAPY, vol. 5, 1994, pages 845 - 852
KOLLS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 215 - 219
MENDELSON ET AL., VIROL., vol. 166, 1988, pages 154 - 165
RAM ET AL., CANCER RES., vol. 53, 1993, pages 83 - 88
ROSENFELD ET AL., SCIENCE, vol. 252, 1991, pages 431 - 434
SAMULSKI ET AL., J VIR., vol. 63, 1989, pages 3822 - 3828
TAKAMIYA ET AL., J. NEUROSCI. RES., vol. 33, 1992, pages 493 - 503
VILE; HART, CANCER RES., vol. 53, 1993, pages 3860 - 3864
VILE; HART, CANCERRES., vol. 53, 1993, pages 962 - 967
WU, 1 BIOL. CHEM., vol. 264, 1989, pages 16985 - 16987

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8602998B2 (en) 2004-03-18 2013-12-10 University of Pittsburgh—of the Commonwealth System of Higher Education Use of relaxin to increase arterial compliance
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Also Published As

Publication number Publication date
EP1854476A3 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
CA2397200C (en) Use of relaxin to treat diseases related to vasoconstriction
EP0600010B1 (de) VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten.
US8602998B2 (en) Use of relaxin to increase arterial compliance
EP0845992B1 (de) Verwendung von relaxin zur stimulierung der angiogenese
US20080280819A1 (en) Methods for promoting hair growth
CA2518550C (en) Cancer treatment using proanp peptides
JP4493913B2 (ja) 低栄養症状疾患治療剤
US7261881B1 (en) Modulation of angiogenesis and wound healing
JP5523408B2 (ja) 動脈コンプライアンスを増加させるためのレラキシンの使用
WO1999059614A1 (en) Modulation of angiogenesis and wound healing
EP1854476A2 (de) Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
US6803359B2 (en) Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
Johansson et al. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070521

AC Divisional application: reference to earlier application

Ref document number: 1253929

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORTHERA, INC.

Owner name: THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JE

Owner name: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1110791

Country of ref document: HK

17Q First examination report despatched

Effective date: 20081121

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110615

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1110791

Country of ref document: HK